The company is a company founded by Chinese and British scientists, focusing on the research and development and application of cell and gene therapy drugs, with "reprogramming technology" as the core. The company's core R & D team comes from Peking University, Cambridge University, Aston University, the UK Sanger Institute and other universities and research institutions, and is committed to converting regenerative medicine research into industrialized cell drugs, and applying the world's leading pluripotent stem cell induction and differentiation technology to the clinic.
The company is based on the independent research and development of an internationally leading iPSC technology platform for the research and development and transformation of downstream cell drugs, and has developed multiple varieties such as endothelial progenitor cells, islet cells, retinal epithelial cells, and tumor antigen affinity peptide-engineered immune cells, and has completed comprehensive pharmaceutical research, in vivo and in vitro preclinical research and IND declaration material preparation. Among them, the IND application for the endothelial progenitor cell injection for stroke was officially approved by the National Medical Products Administration on April 26, 2022, which is the first iPSC-derived cell drug clinical默示 license (IND) in China. At present, it has started clinical Phase I at Beijing Tiantan Hospital to accelerate the application and transformation of the product. The IND application for the CAR-NK product for ovarian cancer was approved on November 11, 2021. Chengnuo Medicine has added two new categories to China's new drug application.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 科创十三街18号院, 锋创科技园13号楼,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.allifetech.com
- HQ
- 北京市, 北京市
- Competitors
- Beijing University of Chinese Medicine Singapore Alumni Association, Jinzhou Jiutai Pharmaceutical Co., Ltd., China Medical University, Beijing University of Chinese Medicine, Well360 Australia, Beijing IMD Science & Technology Co., Ltd, Beijing Scrianen Pharmaceutical Co.,Ltd, The Acupuncture Clinic - Life Blossom Health & Wellness, Allife Medicine, Hebei Jiayi Pharmaceutical Co., Ltd..
Allife Medicine（beijing）limited Questions
Allife Medicine（Beijing）Limited's website is http://www.allifetech.com
Allife Medicine（Beijing）Limited's LinkedIn profile is https://cn.linkedin.com/company/%E5%8C%97%E4%BA%AC%E5%91%88%E8%AF%BA%E5%8C%BB%E5%AD%A6%E7%A7%91%E6%8A%80%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Allife Medicine（Beijing）Limited has
8 employees.
View email and phone details for 8
employees at Allife Medicine（Beijing）Limited.
Allife Medicine（Beijing）Limited's industry is
Biotechnology Research
Allife Medicine（Beijing）Limited's top competitors are
Beijing University Of Chinese Medicine Singapore Alumni Association,
Jinzhou Jiutai Pharmaceutical Co., Ltd.,
China Medical University,
Beijing University Of Chinese Medicine,
Well360 Australia,
Beijing Imd Science & Technology Co., Ltd,
Beijing Scrianen Pharmaceutical Co.,ltd,
The Acupuncture Clinic - Life Blossom Health & Wellness,
Allife Medicine,
Hebei Jiayi Pharmaceutical Co., Ltd..
Allife Medicine（Beijing）Limited's categories are Biotechnology Research
Allife Medicine（Beijing）Limited's founding year is 2017
